This site is intended for health professionals only

Published on 6 July 2007

Share this story:
Twitter
LinkedIn

B-MS drops co-operative HIV venture

teaser

Sweden’s Medivir has been told that partner Bristol-Myers Squibb has terminated development of the firms’ preclinical HIV compound MIV-170.

The decision was taken “because the compound did not meet the profile desired” by the New York-based drugs major. The Swedish firm noted that MIV-170 belongs to a group



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn